Clinical Trials Logo
  1. Home
  2. Other
  3. NCT03689556

Examine the Prognostic Role of FLT PET/CT for Patients With LR-NPC Treated by Carbon Ion Therapy

Recurrent Nasopharyngeal Carcinoma Clinical Trial

Official title:
A Phase II Clinical Trial Evaluating the Role of FLT PET/CT in Predicting Treatment Response of Carbon-ion Radiotherapy for Patients With Locoregionally Recurrent Nasopharyngeal Carcinoma

Clinical Trial Summary

We aim, in this study, to examine whether reduction of FLT PET derived SUV before and after carbon ion radiotherapy can predict the treatment response and survivals for patients with locoregionally recurrent nasopharyngeal carcinoma.

Clinical Trial Description

This is a single-arm phase II clinical trial evaluating the prognostic value of FLT PET/CT for patients with locoregionally recurrent nasopharyngeal carcinoma. All patients will receive FLT PET/CT scans before and after carbon ion radiotherapy (CIRT). The sensitivity and specificity of reduction of FLT uptake reduction in terms of predicting the treatment outcome evaluated by MRI at 3 months after completion of CIRT according to RECIST 1.1. Its predictive value of OS, LPFS, RPFS and DMFS will be examined as well. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03689556
Study type Observational
Source Shanghai Proton and Heavy Ion Center
Contact Lin Kong, MD
Phone +86-21-38296666
Email lin.kong@sphic.org.cn
Status Not yet recruiting
Phase
Start date July 2020
Completion date August 2024
View Details
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06010095 - Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer Phase 2
Recruiting NCT03639467 - Study of Anlotinib Combined With Gemcitabine/Cisplatin in Advanced Nasopharyngeal Carcinoma Phase 1/Phase 2
Recruiting NCT06029270 - Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer Phase 2
Recruiting NCT03666221 - Nimotuzumab for Recurrent Nasopharyngeal Carcinoma Phase 2
Recruiting NCT05350891 - Transnasal Endoscopic Surgery Combined With Adjuvant Immunotherapy for Recurrent NPC Phase 2
Active, not recruiting NCT04586088 - Apatinib and Camrelizumab in Recurrent or Metastatic Nasopharyngeal Carcinoma With First-line Treatment Failure Phase 2
Active, not recruiting NCT04405622 - Toripalimab and Gemcitabine in Recurrent or Metastatic Nasopharyngeal Carcinoma. Phase 2
Recruiting NCT06235203 - Neoadjuvant vs Adjuvant in Locally Advanced Recurrent NPC Phase 3
Not yet recruiting NCT04215510 - Early Recurrent Nasopharyngeal Cancer: the Effect of Surgery vs IMRT Phase 3
Recruiting NCT03907826 - PD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma Patients Phase 3
Recruiting NCT03930498 - Programmed Death-1 (PD-1) Antibody Combined With Chemoradiotherapy in High-risk Recurrent Nasopharyngeal Carcinoma Phase 2
Recruiting NCT04376866 - Toripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma Phase 3
Not yet recruiting NCT05432219 - A Transoral Retropterygoid Approach to Resect Recurrent Nasopharyngeal Carcinoma N/A
Recruiting NCT04425265 - Plasma Radiofrequency Ablation at Low Temperature Versus Electrocautery Block Resection at High Frequency for Localized Recurrent Nasopharyngeal Carcinoma N/A
Not yet recruiting NCT03210389 - A Clinical Trial of Chemotherapy With Lobaplatin and 5-FU in Recurrent Local or Distant Advanced NPC. Phase 2
Completed NCT01370070 - MK-2206 in Recurrent Nasopharyngeal Carcinoma Phase 2
Completed NCT01392235 - Famitinib in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma (NPC) Phase 2
Not yet recruiting NCT06228079 - Adjuvant vs Surgery Only in Early-stage Recurrent NPC Phase 3
Terminated NCT04458909 - Testing the Addition of an Anti-cancer Immune Therapy Drug (Nivolumab) to the Usual Chemotherapy Treatment (Cisplatin or Carboplatin With Gemcitabine) for Recurrent or Metastatic Nasopharyngeal Cancer Phase 3
Withdrawn NCT04231864 - Durvalumab and Epacadostat for Treatment of Unresectable, Recurrent, or Metastatic Epstein-Barr Virus Positive Nasopharyngeal Cancer Phase 2